1. Home
  2. PSNYW vs CMPX Comparison

PSNYW vs CMPX Comparison

Compare PSNYW & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

PSNYW

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

N/A

Current Price

$6.24

Market Cap

398.5M

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

N/A

Current Price

$2.49

Market Cap

408.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSNYW
CMPX
Founded
2017
2014
Country
Sweden
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.5M
408.8M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PSNYW
CMPX
Price
$6.24
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.57
AVG Volume (30 Days)
86.9K
3.1M
Earning Date
03-06-2025
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$79.49
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.61
52 Week High
$9.08
$6.88

Technical Indicators

Market Signals
Indicator
PSNYW
CMPX
Relative Strength Index (RSI) 82.43 61.65
Support Level $2.45 $1.68
Resistance Level $7.50 $5.70
Average True Range (ATR) 0.47 0.14
MACD 0.34 0.03
Stochastic Oscillator 80.40 83.86

Price Performance

Historical Comparison
PSNYW
CMPX

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: